Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHA) EPS (Weighted Average and Diluted) (2018 - 2025)

Innate Pharma posted quarterly EPS (Weighted Average and Diluted) of -$85376.0 for Q2 2025, down 6.88% year-on-year from -$91679.1 in Q2 2024, and down 6.88% on a QoQ basis from -$79883.9 in Q2 2024.

Innate Pharma (IPHA) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$85376.0 in Q2 2025.

  • For the quarter ending Q2 2025, EPS (Weighted Average and Diluted) fell 6.88% year-over-year to -$85376.0; the trailing twelve-month figure through Jun 2025 stood at -$85376.0 (down 6.88% YoY), and the FY2025 full-year result was -$0.64, up 1.78% from the prior year.
  • EPS (Weighted Average and Diluted) for Q2 2025 stood at -$85376.0, down from -$79883.9 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $28400.0 in Q2 2023 and bottomed at -$85376.0 in Q2 2025.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$912.5 (2022), against an average of -$27554.5.
  • The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) sank 1153654.7%; it then jumped 3212.33% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.08 in 2021, then tumbled by 1153654.7% to -$912.5 in 2022, then surged by 3212.33% to $28400.0 in 2023, then sank by 381.28% to -$79883.9 in 2024, then retreated by 6.88% to -$85376.0 in 2025.
  • The last three EPS (Weighted Average and Diluted) figures came in at -$85376.0 (Q2 2025), -$79883.9 (Q2 2024), and $28400.0 (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -4.43
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - 0.00
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 4.02
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 6.75
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 1.51
10 Innate Pharma 199.64 Mn 199.64 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 -85,376.00
Jun 30, 2024 -79,883.87
Jun 30, 2023 28,400.00
Jun 30, 2022 -912.50
Jun 30, 2021 0.08
Jun 30, 2020 -79,492.31
Dec 31, 2018 -293,403.51